Literature DB >> 25038230

Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity.

Gregory J Baker1, Peter Chockley1, Viveka Nand Yadav1, Robert Doherty1, Michael Ritt2, Sivaraj Sivaramakrishnan3, Maria G Castro1, Pedro R Lowenstein4.   

Abstract

Natural killer (NK) cells safeguard against early tumor formation by destroying transformed target cells in a process referred to as NK immune surveillance. However, the immune escape mechanisms used by malignant brain tumors to subvert this innate type of immune surveillance remain unclear. Here we show that malignant glioma cells suppress NK immune surveillance by overexpressing the β-galactoside-binding lectin galectin-1. Conversely, galectin-1-deficient glioma cells could be eradicated by host NK cells before the initiation of an antitumor T-cell response. In vitro experiments demonstrated that galectin-1-deficient GL26-Cit glioma cells are ∼3-fold more sensitive to NK-mediated tumor lysis than galectin-1-expressing cells. Our findings suggest that galectin-1 suppression in human glioma could improve patient survival by restoring NK immune surveillance that can eradicate glioma cells. Cancer Res; 74(18); 5079-90. ©2014 AACR. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25038230      PMCID: PMC4184887          DOI: 10.1158/0008-5472.CAN-14-1203

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

Review 1.  Gene and viral therapy for glioblastoma: a review of clinical trials and future directions.

Authors:  Ahmed Mohyeldin; Ennio Antonio Chiocca
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

2.  Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells.

Authors:  Friederike Gieseke; Judith Böhringer; Rita Bussolari; Massimo Dominici; Rupert Handgretinger; Ingo Müller
Journal:  Blood       Date:  2010-07-19       Impact factor: 22.113

3.  NK cell-depleting anti-asialo GM1 antibody exhibits a lethal off-target effect on basophils in vivo.

Authors:  Hideto Nishikado; Kaori Mukai; Yohei Kawano; Yoshiyuki Minegishi; Hajime Karasuyama
Journal:  J Immunol       Date:  2011-04-13       Impact factor: 5.422

Review 4.  Functions of natural killer cells.

Authors:  Eric Vivier; Elena Tomasello; Myriam Baratin; Thierry Walzer; Sophie Ugolini
Journal:  Nat Immunol       Date:  2008-05       Impact factor: 25.606

Review 5.  Innate or adaptive immunity? The example of natural killer cells.

Authors:  Eric Vivier; David H Raulet; Alessandro Moretta; Michael A Caligiuri; Laurence Zitvogel; Lewis L Lanier; Wayne M Yokoyama; Sophie Ugolini
Journal:  Science       Date:  2011-01-07       Impact factor: 47.728

6.  Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis.

Authors:  Alice Banh; Jing Zhang; Hongbin Cao; Donna M Bouley; Shirley Kwok; Christina Kong; Amato J Giaccia; Albert C Koong; Quynh-Thu Le
Journal:  Cancer Res       Date:  2011-05-05       Impact factor: 12.701

Review 7.  Dendritic cell vaccines for brain tumors.

Authors:  Won Kim; Linda M Liau
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

8.  Mechanism of tumor cell-induced T-cell apoptosis mediated by galectin-1.

Authors:  Ferenc Kovács-Sólyom; Andrea Blaskó; Roberta Fajka-Boja; Róbert L Katona; Lea Végh; Julianna Novák; Gábor János Szebeni; László Krenács; Ferenc Uher; Vilmos Tubak; Robert Kiss; Eva Monostori
Journal:  Immunol Lett       Date:  2009-10-27       Impact factor: 3.685

9.  Gene transfer into rat brain using adenoviral vectors.

Authors:  Mariana Puntel; Kurt M Kroeger; Nicholas S R Sanderson; Clare E Thomas; Maria G Castro; Pedro R Lowenstein
Journal:  Curr Protoc Neurosci       Date:  2010-01

10.  HMGB1 mediates endogenous TLR2 activation and brain tumor regression.

Authors:  James F Curtin; Naiyou Liu; Marianela Candolfi; Weidong Xiong; Hikmat Assi; Kader Yagiz; Matthew R Edwards; Kathrin S Michelsen; Kurt M Kroeger; Chunyan Liu; A K M Ghulam Muhammad; Mary C Clark; Moshe Arditi; Begonya Comin-Anduix; Antoni Ribas; Pedro R Lowenstein; Maria G Castro
Journal:  PLoS Med       Date:  2009-01-13       Impact factor: 11.069

View more
  31 in total

1.  Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells.

Authors:  Gregory J Baker; Maria G Castro; Pedro R Lowenstein
Journal:  J Vis Exp       Date:  2015-11-28       Impact factor: 1.355

Review 2.  Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches.

Authors:  Qin Pan; Qiao Li; Shuang Liu; Ning Ning; Xiaolian Zhang; Yingxin Xu; Alfred E Chang; Max S Wicha
Journal:  Stem Cells       Date:  2015-05-13       Impact factor: 6.277

Review 3.  TGF-β signaling and its targeting for glioma treatment.

Authors:  Jianfeng Han; Christopher A Alvarez-Breckenridge; Qi-En Wang; Jianhua Yu
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

4.  Natural killer cells require monocytic Gr-1(+)/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cells.

Authors:  Gregory J Baker; Peter Chockley; Daniel Zamler; Maria G Castro; Pedro R Lowenstein
Journal:  Oncoimmunology       Date:  2016-03-16       Impact factor: 8.110

Review 5.  CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?

Authors:  Brooke L Prinzing; Stephen M Gottschalk; Giedre Krenciute
Journal:  Expert Rev Anticancer Ther       Date:  2018-03-16       Impact factor: 4.512

Review 6.  Current state and future prospects of immunotherapy for glioma.

Authors:  Neha Kamran; Mahmoud S Alghamri; Felipe J Nunez; Diana Shah; Antonela S Asad; Marianela Candolfi; David Altshuler; Pedro R Lowenstein; Maria G Castro
Journal:  Immunotherapy       Date:  2018-02-01       Impact factor: 4.196

7.  Cracking the glioma-NK inhibitory code: toward successful innate immunotherapy.

Authors:  Pedro R Lowenstein; Gregory J Baker; Maria G Castro
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

Review 8.  Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.

Authors:  Pedro R Lowenstein; Maria G Castro
Journal:  Clin Immunol       Date:  2017-07-15       Impact factor: 3.969

9.  Immune heterogeneity and clinicopathologic characterization of IGFBP2 in 2447 glioma samples.

Authors:  Jinquan Cai; Qun Chen; Yuqiong Cui; Jiawei Dong; Meng Chen; Pengfei Wu; Chuanlu Jiang
Journal:  Oncoimmunology       Date:  2018-02-13       Impact factor: 8.110

Review 10.  Overview of current immunotherapeutic strategies for glioma.

Authors:  Anda-Alexandra Calinescu; Neha Kamran; Gregory Baker; Yohei Mineharu; Pedro Ricardo Lowenstein; Maria Graciela Castro
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.